AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6749189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tests sensitive to small‐airway and large‐airway function and lung volumes
Number of subjects: 0
Study 30527596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multidomain intervention including dietary counseling
Number of subjects: 1260
Study 30527596 — intervention group
Group type: COMPARATOR
Intervention: Regular health advice
Number of subjects: 1260
Study 28990190 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Number of subjects: 36
Study 28990190 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 36
Study 26821876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transversus abdominis plane block using 21 ml of 0.25% bupivacaine and 4.0 mg dexamethasone
Number of subjects: 32
Study 26821876 — intervention group
Group type: COMPARATOR
Intervention: Parenteral opioids alone (sham block with 21 ml 0.9% saline)
Number of subjects: 32
Study 24021723 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated physical activity
Number of subjects: 19
Study 22517769 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE-010 100 μg
Number of subjects: 46
Study 22517769 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE-010 300 μg
Number of subjects: 46
Study 22517769 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE-010 30 μg
Number of subjects: 46
Study 22517769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 22517769 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE-010 (all doses)
Number of subjects: 46
Study 19551441 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic splenectomy (HALS)
Number of subjects: 27
Study 19551441 — intervention group
Group type: COMPARATOR
Intervention: Open splenectomy (OS)
Number of subjects: 27
Study 17387189 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (100 microg x kg(‐1) x min(‐1))
Number of subjects: 52
Study 17387189 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (one minimum alveolar concentration)
Number of subjects: 52
Study 17387189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (one minimum alveolar concentration)
Number of subjects: 52
Study 17387189 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 16085730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure ventilation
Number of subjects: 13
Study 16085730 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume ventilation
Number of subjects: 13
Study 12236441 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.6% carbohydrate‐electrolyte solution (CES)
Number of subjects: 13
Study 12236441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 13
Study 11016338 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum (1200 mL of air injected under the right hemidiaphragm)
Number of subjects: 16
Study 11016338 — intervention group
Group type: COMPARATOR
Intervention: Non-pneumoperitoneum (no air injected)
Number of subjects: 16
Study 8831533 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch anastomosis
Number of subjects: 23
Study 8831533 — intervention group
Group type: COMPARATOR
Intervention: Straight coloanal anastomosis
Number of subjects: 23
Study 1462894 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (rTPA), 1 mg/kg body weight (maximum 100 mg) during 4 hours, in addition to aspirin, heparin, and beta‐blockade
Number of subjects: 205
Study 1462894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 1462894 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator (rTPA)
Number of subjects: 205
Study 6376484 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocarboxazid (active medication)
Number of subjects: 60
Study 6376484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study 30670279 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (10 days of oral vitamin A)
Number of subjects: 74
Study 30670279 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 days of placebo)
Number of subjects: 74
Study 29751754 — intervention group
Group type: EXPERIMENTAL
Intervention: SASA! intervention
Number of subjects: 928
Study 29751754 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 928
Study 27121115 — intervention group
Group type: EXPERIMENTAL
Intervention: High-selenium lentils (65 g per day for 6 months)
Number of subjects: 400
Study 27121115 — intervention group
Group type: COMPARATOR
Intervention: Low-selenium lentils (65 g per day for 6 months)
Number of subjects: 400
Study 27121115 — intervention group
Group type: EXPERIMENTAL
Intervention: High-selenium lentils
Number of subjects: 400
Study 27121115 — intervention group
Group type: COMPARATOR
Intervention: Low-selenium lentils
Number of subjects: 400
Study 24520782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bawei Xilei Powder (BXP)
Number of subjects: 103
Study 24520782 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone edema solution
Number of subjects: 103
Study 22640513 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no intervention reported)
Number of subjects: 1119
Study 20215698 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 27
Study 20215698 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 27
Study 17586582 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (n = 6)
Number of subjects: 20
Study 17586582 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT) (n = 7)
Number of subjects: 20
Study 17586582 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control) (n = 7)
Number of subjects: 20
Study 16398599 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soy protein
Number of subjects: 40
Study 16398599 — intervention group
Group type: COMPARATOR
Intervention: Isolated milk protein
Number of subjects: 40
Study 16398599 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy + probiotic capsules
Number of subjects: 40
Study 16398599 — intervention group
Group type: COMPARATOR
Intervention: Milk + probiotic capsules
Number of subjects: 40
Study 12087922 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg tablet (test formulation)
Number of subjects: 24
Study 12087922 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg tablet (reference formulation)
Number of subjects: 24
Study 10617243 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg simvastatin/d for 6 weeks
Number of subjects: 51
Study 10617243 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin/d for 6 weeks
Number of subjects: 51
Study 10617243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 8538903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg/die (Group A, n = 10)
Number of subjects: 40
Study 8538903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/die (Group B, n = 20)
Number of subjects: 40
Study 8538903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/die + Nitrendipine 20 mg/die (Group C, n = 10)
Number of subjects: 40
Study 31899122 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan (nal-IRI) plus 5-FU
Number of subjects: 0
Study 31899122 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0
Study 29796238 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-based gestural training (four 30-min sessions with a social robot, NAO)
Number of subjects: 30
Study 29796238 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-based gestural training
Number of subjects: 30
Study 29796238 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 30
Study 27179796 — intervention group
Group type: EXPERIMENTAL
Intervention: Body position at -6°
Number of subjects: 10
Study 27179796 — intervention group
Group type: COMPARATOR
Intervention: Body position at 45°
Number of subjects: 10
Study 27179796 — intervention group
Group type: COMPARATOR
Intervention: Body position at 75°
Number of subjects: 10
Study 24291193 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 298
Study 24291193 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with malaria
Number of subjects: 298
Study 24291193 — intervention group
Group type: COMPARATOR
Intervention: Control group (without malaria or helminth infections)
Number of subjects: 298
Study 23114828 — intervention group
Group type: EXPERIMENTAL
Intervention: FP with the conventional rigid bar splinting the implants
Number of subjects: 15
Study 23114828 — intervention group
Group type: COMPARATOR
Intervention: Semi-rigid cantilever extension system with titanium bars placed in the 2 distal abutment cylinders
Number of subjects: 15
Study 21087530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sangustop®
Number of subjects: 126
Study 21087530 — intervention group
Group type: COMPARATOR
Intervention: Tachosil® (carrier-bound fibrin sealant)
Number of subjects: 126
Study 17146370 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) regimens including > or =3 agents
Number of subjects: 1498
Study 15070635 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 614
Study 15070635 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ginkgo and acetazolamide
Number of subjects: 614
Study 15070635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 15070635 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba
Number of subjects: 614
Study 12164804 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange/fresh frozen plasma (PEX/FFP)
Number of subjects: 2
Study 12164804 — intervention group
Group type: COMPARATOR
Intervention: Plasma transfusion
Number of subjects: 2
Study 9586422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (Hex) 2 micrograms/kg/bw i.v.
Number of subjects: 17
Study 9586422 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (Br) 2.5 mg po at time -60
Number of subjects: 17
Study 9586422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9586422 — intervention group
Group type: EXPERIMENTAL
Intervention: Br plus Hex
Number of subjects: 17
Study 9586422 — intervention group
Group type: EXPERIMENTAL
Intervention: Br
Number of subjects: 17
Study 9586422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hex
Number of subjects: 17
Study 8575494 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate 25 mg orally each day
Number of subjects: 90
Study 8575494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 2773665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion
Number of subjects: 11
Study 2773665 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion after ibuprofen
Number of subjects: 11
Study 2773665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside infusion after ibuprofen
Number of subjects: 11
Study 2773665 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 11
Study 1108832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 1108832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31549356 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese moderate persistent asthmatics (Group I)
Number of subjects: 320
Study 31549356 — intervention group
Group type: COMPARATOR
Intervention: Non-obese moderate persistent asthmatics (Group II)
Number of subjects: 320
Study 31276178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail and monetary (guaranteed $10 on screening completion)
Number of subjects: 838
Study 31276178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail and lottery (1 in 10 chance of receiving $50 on screening completion)
Number of subjects: 838
Study 31276178 — intervention group
Group type: COMPARATOR
Intervention: Mail only
Number of subjects: 838
Study 31276178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail and monetary
Number of subjects: 838
Study 31276178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail and lottery
Number of subjects: 838
Study 31276178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail and monetary or mail and lottery for Medicaid patients
Number of subjects: 838
Study 31276178 — intervention group
Group type: COMPARATOR
Intervention: Mail only for non-Medicaid insured
Number of subjects: 838
Study 28152236 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine treatment
Number of subjects: 302
Study 25882337 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 60
Study 25882337 — intervention group
Group type: COMPARATOR
Intervention: First-generation sirolimus-eluting stent (SES)
Number of subjects: 60
Study 23154516 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐SELF Pain Control Program (n = 58)
Number of subjects: 112
Study 23154516 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 54)
Number of subjects: 112
Study 21730080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Number of subjects: 0
Study 21730080 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education Intervention
Number of subjects: 0
Study 19690306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing-led psychoeducational intervention (Project ENABLE) consisting of 4 weekly educational sessions and monthly follow-up sessions until death or study completion (n = 161)
Number of subjects: 322
Study 19690306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing-led psychoeducational intervention (Project ENABLE)
Number of subjects: 322
Study 19690306 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 161)
Number of subjects: 322
Study 17057557 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity Group (n=539)
Number of subjects: 7077
Study 17057557 — intervention group
Group type: COMPARATOR
Intervention: Back Pain Group (n=6538)
Number of subjects: 7077
Study 12937333 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient behavior management only
Number of subjects: 167
Study 12937333 — intervention group
Group type: COMPARATOR
Intervention: Patient behavior management plus caregiver stress-coping management
Number of subjects: 167
Study 12937333 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 167
Study 10716469 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment resolution patterns
Number of subjects: 258
Study 10716469 — intervention group
Group type: COMPARATOR
Intervention: TIMI flow grade
Number of subjects: 258
Study 10716469 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI flow grade 0 & 1 with ST-segment resolution of > or =50%
Number of subjects: 258
Study 9119635 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment (150 mg Pasteur BCG per instillation, 6-week induction course, single maintenance doses for 2 years)
Number of subjects: 94
Study 9119635 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin treatment (50 mg per instillation, early instillation on postoperative day 2, followed by 4 weekly treatments and 10 monthly treatments for 2 years)
Number of subjects: 94
Study 9119635 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment in patients with stage T1 and grade 3 tumours
Number of subjects: 94
Study 1394824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methotrexate, vinblastine, Adriamycin, and cisplatin (M‐VAC)
Number of subjects: 54
Study 1394824 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors analyzed included performance status (PS), M category, and dose of drugs
Number of subjects: 54
Study 1394824 — intervention group
Group type: EXPERIMENTAL
Intervention: M category
Number of subjects: 54
Study 1394824 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of distant metastases
Number of subjects: 54
Study 3157716 — intervention group
Group type: EXPERIMENTAL
Intervention: Queen's Tactile Vocoder
Number of subjects: 2
Study 31005392 — intervention group
Group type: EXPERIMENTAL
Intervention: RP + AVF
Number of subjects: 97
Study 31005392 — intervention group
Group type: COMPARATOR
Intervention: RP
Number of subjects: 97
Study 29341404 — intervention group
Group type: EXPERIMENTAL
Intervention: canagliflozin 100 mg
Number of subjects: 1278
Study 29341404 — intervention group
Group type: EXPERIMENTAL
Intervention: canagliflozin 200 mg
Number of subjects: 1278
Study 26979068 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment
Number of subjects: 93
Study 24915612 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a 180 μg/week
Number of subjects: 200
Study 24915612 — intervention group
Group type: COMPARATOR
Intervention: ETV 0.5mg/day
Number of subjects: 200
Study 22906892 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenum-preserving pancreatic head resection (DPPHR)
Number of subjects: 85
Study 22906892 — intervention group
Group type: COMPARATOR
Intervention: Pylorus-preserving pancreaticoduodenectomy (PPPD)
Number of subjects: 85
Study 22906892 — intervention group
Group type: EXPERIMENTAL
Intervention: DPPHR
Number of subjects: 85
Study 22906892 — intervention group
Group type: COMPARATOR
Intervention: PPPD
Number of subjects: 85
Study 20153063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun exposure practices and attitudes towards sunlight; 60% preferred to be outdoors; 92% believed sunlight was healthy; 90% preferred to be outdoors in their youth.
Number of subjects: 57
Study 20153063 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of greater autonomy and improved physical access; More outdoor leisure activities.
Number of subjects: 57
Study 18433464 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance direct thrombus imaging (MR DTI)
Number of subjects: 43
Study 18433464 — intervention group
Group type: COMPARATOR
Intervention: Compression ultrasound
Number of subjects: 43
Study 16296429 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin‐motor sonic toothbrush (TST)
Number of subjects: 36
Study 16296429 — intervention group
Group type: COMPARATOR
Intervention: Conventional sonic toothbrush (CST)
Number of subjects: 36
Study 16296429 — intervention group
Group type: COMPARATOR
Intervention: Conventional electric toothbrush (CET)
Number of subjects: 36
Study 12063586 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-maintenance with propofol and midazolam (COM-group)
Number of subjects: 40
Study 12063586 — intervention group
Group type: COMPARATOR
Intervention: TIVA with propofol and fentanyl (Control-group)
Number of subjects: 40
Study 9706062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 10 min after 0.04 micrograms/kg IV cholecystokinin (CCK)
Number of subjects: 4
Study 9706062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 30 min after inflation of an occlusive duodenal balloon
Number of subjects: 4
Study 9706062 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine alone (control)
Number of subjects: 4
Study 7618674 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-nitrous oxide in oxygen
Number of subjects: 60
Study 7618674 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone-isoflurane-nitrous oxide-oxygen (control)
Number of subjects: 60
Study 2243896 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide (4 mg p.o.)
Number of subjects: 10
Study 2243896 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline (4 mg p.o.)
Number of subjects: 10
Study 2243896 — intervention group
Group type: COMPARATOR
Intervention: MCPP (0.5 mg/kg p.o.)
Number of subjects: 10
Study 2243896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 445772 — intervention group
Group type: COMPARATOR
Intervention: Persistent medical therapy
Number of subjects: 106
Study 445772 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 106
Study 445772 — intervention group
Group type: EXPERIMENTAL
Intervention: Late surgery
Number of subjects: 106
Study 445772 — intervention group
Group type: EXPERIMENTAL
Intervention: Late surgery patients
Number of subjects: 106
Study 445772 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of late surgery
Number of subjects: 106
Study 31562005 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B birth dose (HepB- BD)
Number of subjects: 344
Study 31562005 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for non-receipt of valid HepB-BD
Number of subjects: 344
Study 31562005 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal recommendations to improve valid HepB-BD uptake
Number of subjects: 344
Study 30294974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (IDE)
Number of subjects: 11
Study 28188383 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady tapping
Number of subjects: 0
Study 28188383 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow tapping
Number of subjects: 0
Study 28188383 — intervention group
Group type: COMPARATOR
Intervention: No tapping
Number of subjects: 0
Study 26260718 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to rudeness (mildly rude statements unrelated to performance)
Number of subjects: 24
Study 26260718 — intervention group
Group type: COMPARATOR
Intervention: Control (neutral comments)
Number of subjects: 24
Study 26260718 — intervention group
Group type: EXPERIMENTAL
Intervention: Rudeness
Number of subjects: 24
Study 26260718 — intervention group
Group type: EXPERIMENTAL
Intervention: Model specifying information-sharing and help-seeking as mediators
Number of subjects: 24
Study 23921271 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 µg/kg/min after a loading dose of 12 µg/kg)
Number of subjects: 30
Study 23921271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21140114 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron plus dexamethasone (PD)
Number of subjects: 30
Study 21140114 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron plus dexamethasone (OD)
Number of subjects: 30
Study 18378859 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 392
Study 18378859 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pulse pressure
Number of subjects: 392